Treatment Strategy for Patients With RA-ILD

Official title

Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease

Overview

This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.

Detailed description

This is a multicenter, randomized, controlled clinical trial designed to evaluate the efficacy and safety of tocilizumab and telitacicept in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). A total of 204 eligible participants will be enrolled from 20 centers across China and randomly assigned in a 1:1:1 ratio to one of three treatment arms: (1) tocilizumab in combination with conventional disease-modifying antirheumatic drugs (cDMARDs); (2) telitacicept in combination with cDMARDs; or (3) methotrexate added to the participant's pre-existing background immunosuppressive regimen. Each treatment arm will include 68 participants. Participants will be assessed at baseline and at Weeks 4, 12, 24, and 52 following treatment initiation. Efficacy and safety data will be collected throughout the study to evaluate treatment response and tolerability. Safety assessments will include the incidence of adverse events (AEs), serious adverse events (SAEs), treatment discontinuations due to AEs or SAEs, and other clinically relevant safety outcomes.

Interventions

• Drug Tocilizumab
  Tocilizumab will be administered intravenously at a dose of 8 mg/kg every 4 weeks in addition to stable background csDMARD therapy maintained throughout the study period.
• Drug Telitacicept
  Telitacicept will be administered by subcutaneous injection at a dose of 160 mg once weekly in addition to stable background csDMARD therapy maintained throughout the study period
• Drug Methotrexate
  Methotrexate will be administered orally at a dose of 15 mg once weekly in addition to stable background csDMARD therapy

Primary outcome measures

• Change in FVC from baseline to week 52 [Time frame: week 52±2]

Secondary outcome measures (6)

• Proportion of Participants Experiencing a Composite Clinical Endpoint [Time frame: Up to Week 52 (±2 Weeks)]
• Change in FVC % Predicted from Baseline [Time frame: Baseline to Week 52 (±2)]
• Change in DLCO from Baseline [Time frame: Baseline to Week 52 (±2 Weeks)]
• Change in DLCO % Predicted from Baseline [Time frame: Baseline to Week 52 (±2 Weeks)]
• Change in Chest HRCT Score from Baseline [Time frame: Baseline to Week 52 (±2 Weeks)]
• Change in mMRC Dyspnea Scale Score from Baseline [Time frame: Baseline to Week 52 (±2 Weeks)]

Eligibility criteria

Inclusion criteria

• Fulfillment of the 2010 ACR/EULAR classification criteria for RA.
• HRCT findings consistent with interstitial lung disease (ILD), including ground-glass opacities, reticular abnormalities, fibrotic linear opacities, traction bronchiectasis, or other compatible features, with pulmonary infection, cardiogenic pulmonary edema, and alveolar hemorrhage excluded. The extent of ILD involvement must be ≥20% on HRCT, as assessed by central review.
• Pulmonary function impairment defined as forced vital capacity (FVC) <80% of predicted and/or diffusing capacity of the lung for carbon monoxide (DLCO) <70% of predicted.
• Participants receiving glucocorticoids prior to enrollment must be on a stable dose of prednisone ≤10 mg/day (or equivalent) for at least 4 weeks before baseline.
• Participants receiving a csDMARD prior to enrollment must be on a stable regimen for at least 4 weeks before baseline.
• Able and willing to provide written informed consent and comply with study requirements, including scheduled visits and follow-up assessments.

Exclusion criteria

• Presence of other autoimmune diseases.
• Presence of severe, uncontrolled clinically significant organ dysfunction or other medical conditions that, in the investigator's judgment, would place the participant at unacceptable risk.
• History of malignancy within 5 years prior to screening.
• Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study period.
• Known hypersensitivity to tocilizumab, telitacicept, methotrexate, or any of their excipients.
• Active hepatitis B or C virus infection, active tuberculosis, active herpes zoster infection, or a history of serious infection within 12 weeks prior to study treatment initiation (defined as an infection requiring hospitalization or intravenous antimicrobial therapy).
• Severe hypoalbuminemia or serum immunoglobulin G (IgG) level <6 g/L.
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × the upper limit of normal (ULN), total bilirubin >1.5 × ULN, or creatinine clearance (CrCl) <60 mL/min.
• Participation in another interventional clinical trial within 4 weeks prior to screening.
• Inability to adequately perform pulmonary function testing or other study-related assessments.
• Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 22 centers

• The First Affiliated Hospital of Henan University of Science and Technology — Luoyang
• Beijing Chao-Yang Hospital, Capital Medical University — Beijing
• China-Japan Friendship Hospital — Beijing
• Peking Union Medical College Hospital — Beijing
• Xuanwu Hospital, Capital Medical University — Beijing
• China-Japan Union Hospital of Jilin University — Changchun
• The First Affiliated Hospital of Army Medical University (Southwest Hospital) — Chongqing
• The Second Affiliated Hospital of Dalian Medical University — Dalian
• … and 14 more centers

Identifiers

NCT: NCT07643038 · Strategy on RA-ILD

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗